SCHEMBL730091

SCHEMBL730091

COC(=O)C(C)(C)c1ccc(Cl)c(N)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CFTR P13569 1/20 0.42
ALDH1A1 P00352 2/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ABL1 P00519 1/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MCHR1 Q99705 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9612065 0.87 CNR1 (0.48) CNR1CNR2NPC1RAB9ACFTR
SCHEMBL1627157 0.85 CNR1 (0.51) CNR1CNR2SMN1; SMN2TSHRMCHR1
SCHEMBL730020 0.82 CNR1 (0.52) CNR1CNR2RAB9ACFTRALDH1A1
SCHEMBL15383148 0.81 CNR2 (0.48) CNR1CNR2RAB9AALDH1A1GAA
SCHEMBL1626715 0.81 CNR1 (0.48) CNR1CNR2RAB9AGAASMN1; SMN2
SCHEMBL25171663 0.81 CNR2 (0.48) CNR1CNR2CFTRALDH1A1GAA
SCHEMBL29990598 0.81 CNR2 (0.48) CNR1CNR2CFTRALDH1A1GAA
Hydrochloric Acid SCHEMBL6978330 0.79 ALDH1A1 (0.50) CNR1CNR2NPC1RAB9ACFTR
SCHEMBL31357589 0.79 CNR2 (0.60) CNR1CNR2RAB9ACFTRALDH1A1
SCHEMBL23582257 0.79 CNR2 (0.60) CNR1CNR2RAB9ACFTRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042870-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2025-02-06 US disclosed
EP-3854781-B1 DP ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2024-05-22 EP disclosed
US-20220204468-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-06-30 US disclosed
US-11319296-B2 DP antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2022-05-03 US disclosed
US-20220033371-A1 DP ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2022-02-03 US disclosed
EP-3854781-A1 DP ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2021-07-28 EP disclosed
CN-112739680-A DP antagonists 小野药品工业株式会社 2021-04-30 CN disclosed
WO-2020059790-A1 DP ANTAGONIST 小野薬品工業株式会社 2020-03-26 WO disclosed
EP-1666473-B1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2013-01-02 EP disclosed
US-8138335-B2 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD (JP) 2012-03-20 US disclosed
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-04 US disclosed
US-7601712-B2 Such as (1)-2-(4-chloro-3-((2-chloro-4-(((2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-ly)methoxy)benzoyl)amino)phenyl)-2-methylpropanoic acid; prostaglandin receptor agonists ONO PHARMACEUTICAL CO., LTD. (JP) 2009-10-13 US disclosed
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-04 US disclosed
CN-1882554-A Carboxylic acid compounds and pharmaceutical compositions containing them as active ingredient ONO PHARMACEUTICAL CO (JP) 2006-12-20 CN disclosed
EP-1666473-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220033371-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 CNR1 2/4885CNR2 4/4885NPC1 553/4885
US-20100029631-A1 CARBOXYLIC ACID COMPOUNDS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT GPR17, CYSLTR1, KIT CNR1 133/4885CNR2 157/4885NPC1 1788/4885
US-20220204468-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 CNR1 2/4885CNR2 4/4885NPC1 553/4885
US-20070004716-A1 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient GPR17, CYSLTR1, KIT CNR1 133/4885CNR2 157/4885NPC1 1788/4885
US-11319296-B2 DP antagonist OPRL1, CNR1, NPSR1 CNR1 2/4885CNR2 4/4885NPC1 553/4885
US-20250042870-A1 DP ANTAGONIST OPRL1, CNR1, NPSR1 CNR1 2/4885CNR2 4/4885NPC1 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.